Impact of Pharmaceutical Care on Quality Of Life in Early Breast Cancer Patients Undergoing Taxane-Based Regimen
Article Sidebar
Main Article Content
Abstract
Objective: To compare the quality of life and severity of adverse reactions in early breast cancer patients undergoing a taxane-based regimen between those receiving pharmaceutical care and those receiving standard care in the hospital. Methods: A randomized controlled trial was conducted among early breast cancer patients treated with a taxane-based regimen at Nopparat Rajathanee Hospital. Subjects were randomly allocated to the pharmaceutical care group (study group) and the standard service group (control group) with a ratio of 1:1. The Thai version of the FACT-B version 4 quality of life assessment form was used to measure the participants' quality of life, while the CTCAE version 5 criteria were employed to assess the severity of adverse drug reactions. Results: A total of forty-nine participants were included in the study, with 25 assigned to the pharmaceutical care group and 24 to standard care group. After receiving chemotherapy, the study group exhibited a significant increase in quality of life from the baseline level (99.71 ± 11.99 to 108.66 ± 12.73; P < 0.001). Moreover, a significant increase in Trial Outcome Index (TOI) was found compared to that at baseline (61.96 ± 8.18 vs 68.40 ± 9.21; P < 0.001) Additionally, the study group experienced a fewer number of peripheral neuropathy at level 3 or higher compared to the control group (0 % vs 16.7%; P = 0.017). Conclusion: Pharmaceutical care using the QOL questionnaire to monitor patients’ adverse drug reactions could improve the quality of life and reduce the severity of adverse drug reactions among early-stage breast cancer patients undergoing a taxane-based chemotherapy regimen.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjo mataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49.
National Cancer Institute. Hospital-based cancer registry 2020 [online]. 2020 [cited May 3 2022]. Available from: www.nci.go.th/e_book/hosbased_256 3/index.html.
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1194-220.
Paoin P, Rungwang Y, Tairsakul R. Quality of life among the breast cancer patients receiving modified radical mastectomy (MRM) and chemotherapy. J Hlth Sci Res 2010; 4: 28-37.
Whelan TJ, Levine M, Julian J, Kirkbride P, Skingley P. The effects of radiation therapy on quality of life of women with breast carcinoma: results of a randomized trial. Cancer 2000; 88: 2260-6.
National Comprehensive Cancer Network. Breast [online]. 2022 [cited May 3 2022]. Available from: www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
Al-Mahayri ZN, Patrinos GP, Ali BR. Toxicity and pharmacogenomic biomarkers in breast cancer chemotherapy. Front Pharmacol. 2020; 11: 445. doi:10.3389/fphar.2020.00445.
De Iuliis F, Salerno G, Taglieri L, Scarpa S. Are phar macogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review. Cancer Chemother Pharmacol 2015; 76: 679-90.
Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC. Past, present, and future challenges in breast cancer treatment. J Clin Oncol 2014; 32: 1979-86.
Korpusilp S, Pongmesa T. Quality of life of breast cancer women during chemotherapy with fluorouracil, doxorubicin and cyclophosphamide (FAC) regimen. Songklanakarind Medical Journal 2017; 35: 373-84.
Subongkot S, Srisawat S, Johns P N, Sookprasert A. Outcome of chemotherapy counseling in oncology patients by pharmacist. Isan Journal of Pharmaceu- tical Sciences. 2009; 5: 34-45.
Cipolle RJ, Starand LM, Morley PC. Pharmaceutical care practice: the patient-centered approach to medication management services. 3rd ed. New York: McGraw-Hill; 2012.
Supapaan T, Amornphetsathaporn J, Jansiri N, Kam-Ing N, Janthapim P, Chompoopuen P. Narrative literature review: outcome measurement of hospital pharmaceutical care in Thailand. Isan Journal of Pharmaceutical Sciences. 2021; 17: 1-29.
Hepler CD, Strand LM. Opportunities and responsi bilities in pharmaceutical care. Am J Hosp Pharm 1990; 47: 533-43.
Fujii H, Ueda Y, Hirose C, Ohata K, Sekiya K, Kita hora M, et al. Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy. J Pharm Health Care Sci 2022; 8: 8 doi:10.1186/s4078 0-022-00239-w.
Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W, et al. Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer 2012; 20: 2669-77.
Trevittaya P. Concepts of quality of life. J Assoc Med Sci 2016; 49: 171-84.
Bottomley A, Reijneveld JC, Koller M, Flechtner H, Tomaszewski KA, Greimel E, et al. Current state of quality of life and patient-reported outcomes research. Eur J Cancer 2019; 121: 55-63.
Turner-Bowker DM, Hao Y, Foley C, Galipeau N, Mazar I, Krohe M, et al. The use of patient-reported outcomes in advanced breast cancer clinical trials: a review of the published literature. Curr Med Res Opin 2016; 32: 1709-17.
Chuenchom O, Chuemongkon W, Rattanacheeworn K, Kasemsakkarin W. The Comparison of the quality of life in patients with early stage breast cancer between using FAC and AC-T regimens in Marengrai roke clinic at Maharat Nakhon Ratchasima Hospital. Isan Journal Pharmaceutical Sciences 2014; 10: 214 -27.
Mokhtari-Hessari P, Montazeri A. Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018. Health Qual Life Out- comes 2020; 18: 338. doi:10.1186/s12955-020-01591-x.
Lovelace DL, McDaniel LR, Golden D. Long-term effects of breast cancer surgery, treatment, and survivor care. J Midwifery Womens Health 2019; 64: 713-24.
Wongkray S, Danwilai K DT. Impact of pharmaceutical care on quality of life in breast cancer patients: a randomized controlled trial. Thai Journal of Pharmacy Practice 2019; 11: 827-39.
Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav Res Methods 2009; 41: 1149-60.
Common terminology criteria for adverse events (CTCAE) Ver 5.0 Department of health and human
services [online]. 2017 [cited April 5, 2022]. Available from: ctep.cancer.gov/protocoldevelopment/electro nic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997; 15: 974-86.
Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-15.
Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004; 57: 898-910.
Clavarezza M, Del Mastro L, Venturini M. Taxane-containing chemotherapy in the treatment of early breast cancer patients. Ann Oncol 2006; 17: vii22-vii6.
Intamnu S. Effects of counseling and monitoring of adverse drug events (ADE) in patients with breast and colorectal cancer receiving chemotherapy in Nangrong hospital. Thai Journal of Pharmacy Prac- tice 2021; 13: 202-13.
Hong-Li C, Xiao-Chun W, Jiang-Bin W, Jing-Bo Z, Yao W. Quality of life in patients with breast cancer and their rehabilitation needs. Pak J Med Sci 2014; 30: 126-30.